Jaeb Center for Health Research (JCHR)

See schedule o during 2022, jchr had 49 active clinical studies. In addition to industry collaborations, jchr received grants from the national institutes of Health (8), helmsley charitable trust (10), jdrf (5), Foundation fighting blindness (5), cystic fibrosis Foundation (2), and food and drug administration (1). Jchr also self-funded one study and numerous statistical analysis projects using datasets from previously completed studies. Several studies are funded by multiple sources. for example, one clinical trial evaluating fenofibrate for diabetic retinopathy is a large collaboration with funds provided by the national institutes of Health (national eye institute and national institute of diabetes and digestive and kidney disease), jdrf, helmsley charitable trust, and roche. Nine new grants, contracts, or subawards began during the year. Among 2,859 entities receiving nih funding in 2022, jchr ranks in the top 9%. Out of 65,306 nih grants provided in 2022, jchr had the 173rd (top 0.3%) and 581st (top 0.9%) largest grants (source: blue ridge institute for medical Research, 2022). Jchr projects had 62 manuscripts accepted or published and 53 presentations made at national and international meetings in 2022. Results from these manuscripts include the following four that were published in the new england journal of medicine: a randomized trial of bionic pancreas treatment in type 1 diabetes demonstrated that at 13 weeks, bionic pancreas use was associated with a greater reduction in hba1c than standard care. Unlike currently available semiautomated insulin-delivery systems, the bionic pancreas does not require carbohydrate counting for routine operation. A randomized trial in very young children with type 1 diabetes (ages 1 to 7) showed improved glycemic control with the use of a hybrid closed-loop system (i.e., artificial pancreas) without increasing time spent in hypoglycemic range. A randomized trial in youths (10 to <17 years) with new onset type 1 diabetes demonstrated that hybrid closed-loop therapy did not prevent the decline of residual c-peptide secretion over 24 months compared with standard insulin treatment. A randomized trial in eyes with diabetic macular edema with moderate vision loss found no significant difference in visual acuity over two years between injections of aflibercept monotherapy (~$1,830 per injection) and injections of bevacizumab first (~$70 per injection) with a switch to aflibercept when there was suboptimal response.in addition to conventional clinic-based clinical trials, jchr conducted several "direct to-patient" studies in which jchr staff had virtual contact with study participants who provided data via the internet and from devices: (1) a study to collect device data during exercise in adults with type 1 diabetes; (2) a study to collect device data during exercise in youth with type 1 diabetes; (3) a study to provide virtual clinic support for adults with type 1 or type 2 diabetes that included support for the use of diabetes technology as well as behavioral Health support; and (4) a study to collect real-world data from a diabetes management system that displays and tracks healthcare provider-recommended insulin dosing information.